Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

References

• World Health OrganizationChronic respiratory diseases. Burden of COPD Available from: http://www.who.int/respiratory/copd/burden/en/Accessed January 17, 2014
   Google Scholar
• CanningBJReflex regulation of airway smooth muscle toneJ Appl Physiol2006101397198516728519
   PubMed Web of Science ®Google Scholar
• MoultonBCFryerADMuscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPDBr J Pharmacol20111631445221198547
   PubMed Web of Science ®Google Scholar
• JacobyDBFryerADAnticholinergic therapy for airway diseasesLife Sci20016822–232565257211392627
   PubMed Web of Science ®Google Scholar
• SharafkhanehAMajidHGrossNJSafety and tolerability of inhalational anticholinergics in COPDDrug Healthc Patient Saf20135495523526112
   PubMedGoogle Scholar
• ReidDJPhamNTEmerging therapeutic options for the management of COPDClin Med Insights Circ Respir Pulm Med2013771523641160
   PubMedGoogle Scholar
• EglenRMChoppinADillonMPHegdeSMuscarinic receptor ligands and their therapeutic potentialCurr Opin Chem Biol19993442643210419852
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGD’AmatoGEvidence of muscarinic receptor subtypes in airway smooth muscle of normal volunteers and of chronic obstructive pulmonary disease patientsInt J Clin Pharmacol Res19899165702707927
   PubMedGoogle Scholar
• SentellasSRamosIAlbertíJAclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolitesEur J Pharm Sci201039528329020093184
   PubMed Web of Science ®Google Scholar
• AlbertíJMartinetASentellasSSalvàMIdentification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromideDrug Metab Dispos20103871202121020332199
   PubMed Web of Science ®Google Scholar
• de la MotteSBeierJSchmidKPascualSJansatJMGilEGPharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary diseaseInt J Clin Pharmacol Ther201250640341222541745
   PubMed Web of Science ®Google Scholar
• JansatJMLamarcaRGarcia GilEFerrerPSafety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjectsInt J Clin Pharmacol Ther200947746046819640353
   PubMed Web of Science ®Google Scholar
• SchmidKPascualSGilEGOrtizSJansatJMPharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a Phase I, open-label, single-dose clinical trialClin Ther201032101798181221194604
   PubMed Web of Science ®Google Scholar
• GavaldàAGrasJLlupiàJAubetsJBeletaJLlenasJAclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profileLife Sci2012907–830130522213116
   PubMed Web of Science ®Google Scholar
• OrtizSFlachSHoJMass balance and metabolism of aclidinium bromide following intravenous administration of [¹4C]-aclidinium bromide in healthy subjectsBiopharm Drug Dispos2012331394522275272
   PubMed Web of Science ®Google Scholar
• PratMFernándezDBuilMADiscovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl) acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.22]octane bromide (aclidinium bromide)J Med Chem200952165076509219653626
   PubMed Web of Science ®Google Scholar
• SentellasSRamosIAlbertíJAclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolitesEur J Pharm Sci201039528329020093184
   PubMed Web of Science ®Google Scholar
• LasseterKCAubetsJChuecosFGilEGAclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjectsJ Clin Pharmacol201151692393220959525
   PubMed Web of Science ®Google Scholar
• D’UrzoAKerwinERennardSHeTGilEGCaractaCOne-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPDCOPD201310450051023679347
   PubMedGoogle Scholar
• GelbAFTashkinDPMakeBJZhongXGarcia GilECaractaCLAS-MD-35 Study InvestigatorsLong-term safety and efficacy of twice-daily aclidinium bromide in patients with COPDRespir Med2013107121957196523916502
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• SinghDMagnussenHKirstenAA randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patientsPulm Pharmacol Ther201225324825322497752
   PubMed Web of Science ®Google Scholar
• MaltaisFCelliBCasaburiRAclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPDRespir Med2011105458058721183326
   PubMed Web of Science ®Google Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest2012141374575221903737
   PubMed Web of Science ®Google Scholar
• BeierJKirstenAMMrûzREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb studyCOPD201310451152223819698
   PubMedGoogle Scholar
• US Food and Drug AdministrationNDA 202-450: aclidinium bromide for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysemaPaper presented at the Pulmonary Allergy Drugs Advisory Committee MeetingFebruary 23, 2012Silver Spring, MD, USA Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM292620.pdfAccessed August 30, 2012
   Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• MilaraJSerranoAPeiróTAclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transitionEur Respir J20134161264127423018909
   PubMed Web of Science ®Google Scholar
• MilaraJSerranoAPeiróTAclidinium inhibits human lung fibroblast to myofibroblast transitionThorax201267322923721957094
   PubMed Web of Science ®Google Scholar
• CortijoJMataMMilaraJAclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airwaysEur Respir J201137224425420525722
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCMateraMGLong-acting muscarinic receptor antagonists for the treatment of respiratory diseasePulm Pharmacol Ther201326330731723274274
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPMateraMGAclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother201314677578123472632
   PubMed Web of Science ®Google Scholar